Dr. Drapkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Jimmy Fund Way
Danafarber Cancer Institute Smith 810
Boston, MA 02115Phone+1 617-632-4380Fax+1 617-632-4381
Summary
- Dr. Ronny Drapkin is a physician-scientist in Philadelphia, PA affiliated with the University of Pennsylvania Perelman School of Medicine. He received his MD and PhD degrees from Rutgers Robert Wood Johnson Medical School followed by a residency in Pathology at the Brigham & Women's Hospital in Boston. He completed a postdoctoral fellowship at the Dana-Farber Cancer Institute before joining the faculty at Harvard Medical School and the DFCI. He was recruited to Penn in 2015. He also speaks multiple languages, including Spanish. He specializes in anatomic pathology. He has more than 230 publications and over 30,000 citings.
Education & Training
Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 2001 - 2006
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2001
Rutgers Robert Wood Johnson Medical SchoolClass of 1998
Rutgers Graduate School of Biomedical SciencesPhD, Biochemistry, 1992 - 1996- Brandeis UniversityBA, 1986 - 1990
Certifications & Licensure
MA State Medical License 2001 - 2016
Awards, Honors, & Recognition
- Inducted Member American Association of Physicians (AAP), 2023
- Rosalind Franklin Prize for Excellence in Ovarian Cancer Research Ovarian Cancer Research Fund Alliance, 2017
- Inducted Member American Society for Clinical Investigation (ASCI), 2016
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsKDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.Heng Liu, Jianhuang Lin, Wei Zhou, Renyta Moses, Zhongping Dai
Cancer Immunology Research. 2022-08-03 - 388 citationsTransformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten ModelsRuth Perets, Gregory A. Wyant, Katherine W. Muto, Jonathan G. Bijron, Barish B. Poole
Cancer Cell. 2013-12-09 - 184 citationsPathogenesis and heterogeneity of ovarian cancer.Paul T. Kroeger, Ronny Drapkin
Current Opinion in Obstetrics & Gynecology. 2017-02-01
Journal Articles
- Primordial Germ Cells as a Potential Shared Cell of Origin for Mucinous Cystic Neoplasms of the Pancreas and Mucinous Ovarian TumorsLeona A Doyle, Daniel W Cramer, Michael Goggins, Ronny Drapkin, Jason L Hornick, Kevin M Elias, Michael Birrer, Michelle S Hirsch, The Journal of Pathology
Press Mentions
Six Warning Signs of Ovarian CancerMay 8th, 2023- Five Bizarre Warning Signs of Ovarian Cancer RevealedMarch 7th, 2023
- Five Bizarre Warning Signs of Ovarian Cancer RevealedMarch 7th, 2023
- Join now to see all
Grant Support
- PROTEOMIC GENETIC AND LONGITUDINAL PATHS TO OVARIAN CANCER BIOMARKER DISCOVERYNATIONAL CANCER INSTITUTE2014–Present
- PACIFIC OVARIAN CANCER RESEARCH CONSORTIUMNATIONAL CANCER INSTITUTE1999–Present
- Cyclin E1 as a Therapeutic Target in Women with High-Grade Serous Ovarian Cancer and Primary Treatment FailurePMCC/Dept. of the Army – USAMRAA2015–2018
- Cyclin E: Targeting Cell Cycle Dependencies in Ovarian CancerAdelson Medical Research Foundation (AMRF)2014–2017
- ELAFIN AS A BIOMARKER IN SEROUS OVARIAN CANCERS AND BASAL-LIKE BREAST TUMORSNational Cancer Institute (NCI)2013–2015
- BACH1 Function In DNA Repair And Mammary OncogenesisNational Cancer Institute2005–2009
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
External Links
- Drapkin Labhttps://www.med.upenn.edu/drapkinlab/
- Drapkin @ Pennhttp://www.uphs.upenn.edu/obgyn/research/ovarian.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
